Esperion Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ESPR and other ETFs, options, and stocks.

About ESPR

Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets.

CEO

Sheldon L. Koenig

CEOSheldon L. Koenig

Employees

294

Employees294

Headquarters

Ann Arbor, Michigan

HeadquartersAnn Arbor, Michigan

Founded

1998

Founded1998

Employees

294

Employees294

ESPR Key Statistics

Market cap

810.83M

Market cap810.83M

Price-Earnings ratio

-15.04

Price-Earnings ratio-15.04

Dividend yield

—

Dividend yield—

Average volume

30.20M

Average volume30.20M

High today

$3.15

High today$3.15

Low today

$3.13

Low today$3.13

Open price

$3.15

Open price$3.15

Volume

12.11M

Volume12.11M

52 Week high

$4.18

52 Week high$4.18

52 Week low

$0.6925

52 Week low$0.6925

Stock Snapshot

The current Esperion Therapeutics(ESPR) stock price is $3.15, with a market capitalization of 810.83M. The stock trades at a price-to-earnings (P/E) ratio of -15.04.

On 2026-05-07, Esperion Therapeutics(ESPR) stock moved within a range of $3.13 to $3.15. With shares now at $3.15, the stock is trading +0.6% above its intraday low and 0.0% below the session's peak.

Trading activity shows a volume of 12.11M, compared to an average daily volume of 30.2M.

The stock's 52-week range extends from a low of $0.69 to a high of $4.18.

ESPR News

TipRanks 3d

Esperion downgraded to Hold from Buy at Needham

Needham downgraded Esperion (ESPR) to Hold from Buy after the company announced it will be acquired by Archimed for $3.16 per share and a $100M contingent value...

TipRanks 5d

Esperion Stock Surges Onto Analysts’ Trending Radar

Analysts are intrested in these 5 stocks: ( (ESPR) ). Here is a breakdown of their recent ratings and the rationale behind them. Claim 55% Off TipRanks Unlock h...

TipRanks 6d

Esperion agrees to $1.1 billion ARCHIMED buyout

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

86%

of 7 ratings

Buy

Hold

85.7%

Sell

14.3%

More ESPR News

Nasdaq 6d

Esperion Agrees To Be Acquired By ARCHIMED In Deal Worth Upto $1.1 Bln, Stock Up

(RTTNews) - Esperion Therapeutics (ESPR), a biopharmaceutical company, on Friday announced that it has agreed to be acquired by funds managed by healthcare inve...

People also own

Based on the portfolios of people who own ESPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.